Most Read Articles
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
24 Aug 2016

Roshini Claire Anthony spoke with Adjunct Associate Professor Gamaliel Tan, head and senior orthopaedic consultant at Ng Teng Fong Hospital in Singapore, on how GPs can help diagnose and treat lower back pain.

Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

15 Nov 2017
The β2 adrenoreceptor agonist salbutamol, a brain-penetrant asthma medication, appears to reduce the risk of developing Parkinson’s disease, possibly through the epigenetic suppression of SNCA—the gene that encodes α-synuclein, according to a study.

R2CHOP reduces CNS relapse in diffuse large B-cell lymphoma

10 Jul 2018
Kanker darah, seperti leukemia, Hodgkin lymphona, non-Hodgkin lymphoma dan multiple myeloma

Adding lenalidomide to the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; R2CHOP) frontline therapy for diffuse large B-cell lymphoma (DLBCL) reduces the rate of central nervous system (CNS) relapse, according to a recent study.

Accessing records from two R2CHOP trials, researchers grouped 136 DLBCL patients into three groups of low (n=14; median age 56.5 years), intermediate (n=97; median age 69 years) and high (n=25; median age 69 years) risk of CNS relapse. The Kaplan-Meier method was used to estimate relapse rates, which were then compared among groups.

Only one of the participants developed isolated CNS relapse, yielding an incidence rate of 0.7 percent. The time to relapse was 10 months and the event occurred 6 months after a complete treatment response was achieved. The participant belonged to the high-risk group.

The Kaplan-Meier estimate for the 2-year relapse rate was 0.9 percent for the entire R2CHOP cohort. The corresponding values for the low-, intermediate- and high-risk groups were 0, 0 and 5.0 percent. Compared with database patients treated with R-CHOP only, the 2-year CNS relapse rate for R2CHOP was lower (0.9 percent vs 1.8 percent).

The same was true for the low- (0 percent vs 1.4 percent) and intermediate- (0 percent vs 2.2 percent) risk groups, but not the high-risk patients (5.0 percent vs 1.1 percent).

The findings support further studies on the value of lenalidomide in decreasing CNS relapse in DLBCL patients, said researchers, noting that involving clinical and molecular factors in patient risk stratification may be an effective approach.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
24 Aug 2016

Roshini Claire Anthony spoke with Adjunct Associate Professor Gamaliel Tan, head and senior orthopaedic consultant at Ng Teng Fong Hospital in Singapore, on how GPs can help diagnose and treat lower back pain.

Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

15 Nov 2017
The β2 adrenoreceptor agonist salbutamol, a brain-penetrant asthma medication, appears to reduce the risk of developing Parkinson’s disease, possibly through the epigenetic suppression of SNCA—the gene that encodes α-synuclein, according to a study.